Luyan Pharmaceutical Hits Daily Limit Driven by Flu and Medical Insurance Catalysts

According to on-site data collected by tushare_zt_pool at 17:15 (UTC+8) on December 17, 2025, Luyan Pharmaceutical hit the daily limit at 12.64 yuan with a trading volume of 70.11 million shares and a turnover rate of 14.3%, reflecting a high concentration of short-term capital driven by themes [0]. The earlier expected flu peak, peak forecasts released by the Shanghai and Guangdong CDC, and the company’s confirmation in the investor Q&A on December 10 that anti-flu drugs such as oseltamivir and baloxavir marboxil are in its business line have formed a direct demand association [1][2][3]. The access of innovative drugs brought by the adjustment of the medical insurance catalog has enhanced the bargaining power of pharmaceutical distribution enterprises. The inclusion of medium and high-priced anti-flu varieties in both medical insurance and commercial insurance channels has further expanded the volume and price space [4][5]. As a result, the cold chain logistics/pharmaceutical distribution sector has attracted institutional capital (main net inflow of 12.2298 million yuan on December 15), and the superposition of the flu theme has caused this stock to differentiate within the sector [6].

Technically, the trading volume has hit new highs for two consecutive days and the price has reached a 52-week high, but overbought signals such as KDJ and RSI are significant, and the short-term oversold rebound space is limited; currently, Beta is far below 0.3, indicating that its daily fluctuations are weakly affected by the market. Whether it can maintain the daily limit in the short term needs to observe the stability of the closing orders and the continuity of capital [0]. Market sentiment shows differentiation among pharmaceutical distribution stocks, with capital concentrating on themes. The overall medical sector did not rise synchronously, indicating that Luyan Pharmaceutical’s daily limit is driven by a specific story rather than following the sector trend [0].

1. The earlier start of the flu peak expectation, combined with the company’s disclosed anti-flu varieties and the access optimization brought by the medical insurance catalog, has formed a superposition of short-term revenue imagination, which helps explain the rapid inflow of institutional and individual capital [1][2][3][4][5].
2. Technical indicators have shown overbought conditions, and the trading volume has increased after the daily limit, indicating that the current rebound lacks phased adjustment support. If capital withdraws or transactions fall back, the stock price may quickly return to the 11-12 yuan range [0].
3. Although the market did not rise synchronously, the cold chain/pharmaceutical distribution positioning of this stock can still benefit from seasonal demand and capital distribution, indicating that the theme direction has a certain independence, but it also emphasizes the need to closely observe the main net flow direction and the evolution of closing orders [6][0].

• Technically, the overbought risk is obvious (high KDJ J value, high RSI). If the closing order pressure cannot continue after the daily limit, it may quickly trigger a short-term callback [0].
• The flu theme has strong seasonality (usually concentrated from December to March of the next year). If the peak period passes earlier or the epidemic data is lower than expected, the demand enthusiasm will quickly fall back [2][3][5].
• Whether the trading volume can continue after consecutive magnification is the key. If high volume cannot be maintained or large selling orders appear on December 18, the daily limit may be opened [0].
• Opportunity: The expansion of the medical insurance catalog and commercial insurance provides a broader market for anti-flu drugs. If subsequent performance or sales data prove that the demand side is real, it can extend the theme’s continuity [4][5].
• Opportunity: Capital in the cold chain/pharmaceutical distribution sector tends to favor such stable defensive stocks, and the short-term rotation logic can bring directional capital support to it [6].

• Luyan Pharmaceutical hit the daily limit at 12.64 yuan with a trading volume of 70.11 million shares on the day, with a high concentration of short-term capital, reflecting the strength driven by themes [0].
• The company confirmed on December 10 that it operates mainstream anti-flu drugs. The earlier expected flu peak and faster virus transmission form a demand increment logic [1][2][3].
• The relaxation of the medical insurance catalog accompanied by new commercial insurance channels provides policy-driven medium-term benefits for anti-flu drugs and pharmaceutical distribution enterprises [4][5].
• The joint force of sector capital inflow and cold chain concept highlights the theme independence of this stock, but it is necessary to continuously monitor capital trends and the quality of daily limit closing orders [6][0].
• Technically, it has shown overbought conditions. A callback may occur in the range of 11.50-12.00 yuan in the short term for reconfirmation. The subsequent trend needs to observe the progress of the epidemic and the continuity of capital [0].